ADMA Biologics, Inc. (NASDAQ:ADMA) Director Sells $1,095,600.00 in Stock

ADMA Biologics, Inc. (NASDAQ:ADMA) Director Young Kwon sold 60,000 shares of the firm’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the transaction, the director now directly owns 241,441 shares in the company, valued at $4,408,712.66. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

ADMA Biologics Stock Down 0.1 %

ADMA opened at $17.22 on Friday. The company has a market capitalization of $3.99 billion, a PE ratio of -861.00 and a beta of 0.55. The firm has a 50-day simple moving average of $13.74 and a two-hundred day simple moving average of $9.54. The company has a quick ratio of 1.86, a current ratio of 5.21 and a debt-to-equity ratio of 0.91. ADMA Biologics, Inc. has a 52 week low of $3.06 and a 52 week high of $18.48.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. ADMA Biologics had a positive return on equity of 17.24% and a negative net margin of 1.29%. The company had revenue of $107.20 million during the quarter, compared to analyst estimates of $86.44 million. During the same period in the prior year, the company earned ($0.02) earnings per share. The firm’s revenue was up 78.4% on a year-over-year basis. Analysts forecast that ADMA Biologics, Inc. will post 0.35 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on ADMA. HC Wainwright raised their price objective on ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Mizuho raised their target price on shares of ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, June 20th. Cantor Fitzgerald upped their price target on shares of ADMA Biologics from $15.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, August 9th. Finally, Raymond James increased their price target on ADMA Biologics from $8.00 to $10.00 and gave the stock a “strong-buy” rating in a research note on Friday, May 10th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, ADMA Biologics has an average rating of “Buy” and a consensus target price of $15.50.

Institutional Investors Weigh In On ADMA Biologics

Several large investors have recently bought and sold shares of ADMA. Quest Partners LLC bought a new position in ADMA Biologics during the second quarter valued at $29,000. EntryPoint Capital LLC purchased a new position in ADMA Biologics in the first quarter worth about $31,000. Simplicity Wealth LLC bought a new stake in ADMA Biologics during the first quarter worth approximately $68,000. AJOVista LLC bought a new stake in ADMA Biologics during the fourth quarter worth approximately $77,000. Finally, Oxford Asset Management LLP purchased a new stake in ADMA Biologics during the fourth quarter valued at approximately $83,000. Institutional investors own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.